Ultragenyx Pharmaceutical Inc.’s Free Cash Flow Growth at a glance
Ultragenyx Pharmaceutical Inc. reports free cash flow growth of 19.2% for Dec 2024. The prior period recorded 0.95% (Dec 2023). Year over year the metric moved +18.2 pts (+1,911.1%). The rolling three-period average stands at -2.6%. Data last refreshed Dec 7, 2025, 2:56 AM.
Latest reading
19.2% · Dec 2024
YoY movement
+18.2 pts (+1,911.1%)
Rolling average
-2.6%
Current Free Cash Flow Growth
19.2%
+18.2 pts
+1,911.1%
Rolling average
-2.6%
Latest Value
19.2%
Dec 2024
YoY Change
+18.2 pts
Absolute
YoY Change %
+1,911.1%
Rate of change
3-Period Avg
-2.6%
Smoothed
Narrative signal
Ultragenyx Pharmaceutical Inc.’s free cash flow growth stands at 19.2% for Dec 2024. Year-over-year, the metric shifted by +18.2 pts, translating into a +1,911.1% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How free cash flow growth shapes Ultragenyx Pharmaceutical Inc.'s story
As of Dec 2024, Ultragenyx Pharmaceutical Inc. reports free cash flow growth of 19.2%. Gauge reinvestment strength and capital return capacity using free cash flow growth over multiple reporting periods.
Cash flow versus earnings
Free cash flow growth can diverge from earnings due to working capital and capex swings. Track both to confirm quality.
Capital allocation insights
Rising free cash flow enables dividends, buybacks, and debt reduction—key levers for shareholder value.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
86.3%
Operating Margin
-95.7%
Net Profit Margin
-101.6%
Return on Equity
-222.9%
Return on Assets
-37.9%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Ultragenyx Pharmaceutical Inc. (RARE) FAQs
Answers tailored to Ultragenyx Pharmaceutical Inc.’s free cash flow growth profile using the latest Financial Modeling Prep data.
What is Ultragenyx Pharmaceutical Inc.'s current free cash flow growth?
As of Dec 2024, Ultragenyx Pharmaceutical Inc. reports free cash flow growth of 19.2%. This reading reflects the latest filings and price data for RARE.
How is Ultragenyx Pharmaceutical Inc.'s free cash flow growth trending year over year?
Year-over-year, the figure shifts by +18.2 pts (+1,911.1%). Pair this context with revenue growth and free cash flow signals to gauge momentum for RARE.
Why does free cash flow growth matter for Ultragenyx Pharmaceutical Inc.?
Free cash flow growth measures how quickly operating cash surplus expands compared with the prior period. For Ultragenyx Pharmaceutical Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Ultragenyx Pharmaceutical Inc.'s free cash flow growth above its recent average?
Ultragenyx Pharmaceutical Inc.'s rolling three-period average sits at -2.6%. Comparing the latest reading of 19.2% to that baseline highlights whether momentum is building or fading for RARE.
How frequently is Ultragenyx Pharmaceutical Inc.'s free cash flow growth refreshed?
Data for RARE was last refreshed on Dec 7, 2025, 2:56 AM and updates automatically every 24 hours, keeping your valuation inputs current.